NLRP3 inflammasome inhibitors (Ventyx Biosciences)

N/A

Report date: 2024/08/16 20:00:38
NME

Base Information

Drug NameNLRP3 inflammasome inhibitors (Ventyx Biosciences)
Drug Alias NameVTX-3232
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionNACHT, LRR and PYD domains-containing protein 3 inhibitors
TargetsNACHT, LRR and PYD domains-containing protein 3
Therapy Area/IndicationsObesityParkinson Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesVentyx Biosciences Inc
China Registration ClassN/A

Develop Information

Active CompaniesZomagen Biosciences LtdVentyx Biosciences Inc
Inactive CompaniesN/A
Active IndicationsObesityParkinson Disease
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A